Concord Medical Services (CCM) AI Stock Analysis

• Market Cap: $25.18M
• Dividend Yield: N/A
• Average Volume (3M): 5.22K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.36
• Revenue Growth: -29.82%
• EPS Growth: -2.57%
• Country: US
• Employees: 595
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Care Facilities
• EPS (TTM): -9.83
• Shares Outstanding: 2,815,458
• 10 Day Avg. Volume: 2,340
• 30 Day Avg. Volume: 5,219
• PEG Ratio: 0.75
• Price to Book (P/B): -7.95
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -24.69
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 39 Underperform
• Price Target: $6.00 ▲(3.45%Upside)

The overall stock score for Concord Medical Services is significantly impacted by its poor financial performance, characterized by declining revenues, high leverage, and negative cash flows. Technical analysis indicates bearish momentum, and valuation metrics are unfavorable, with a negative P/E ratio and no dividend yield. These factors collectively contribute to a low overall stock score, highlighting considerable risk.

Concord Medical Services Business Overview & Revenue Model

Company Description

Concord Medical Services Holdings Limited (CCM) is a healthcare company that operates in the medical services sector, primarily focusing on providing specialty hospital management services and diagnostic imaging services. The company is based in China and is known for its extensive network of medical centers, which offer a wide range of services including radiotherapy, oncology, and diagnostic imaging. Concord Medical Services aims to enhance the quality of healthcare services in the regions it operates by leveraging advanced medical technologies and expertise.

How the Company Makes Money

Concord Medical Services generates revenue through several key streams. The primary source of income is from its network of medical centers, which offer diagnostic imaging services such as MRI, CT scans, and other advanced imaging technologies. Additionally, the company earns money through providing radiotherapy and oncology services. Concord Medical also engages in hospital management services, where it partners with hospitals to manage their radiotherapy and diagnostic imaging departments, sharing revenue from these operations. These strategic partnerships and the growing demand for specialized medical services in China contribute significantly to its earnings.

Concord Medical Services Financial Statement Overview

Summary

Concord Medical Services faces severe financial difficulties, with significant revenue decline, negative gross and net profit margins, and a highly leveraged balance sheet. The company struggles with negative cash flows and relies unsustainably on external financing.

Income Statement

Concord Medical Services has experienced a persistent decline in revenue with a sharp drop from $537M in 2023 to $384M in 2024. Negative gross profit and EBIT margins indicate significant operational challenges. The net profit margin remains deeply negative, reflecting ongoing financial struggles.

Balance Sheet

The company's balance sheet shows considerable financial distress, with negative stockholders' equity reflecting a heavily leveraged position. The debt-to-equity ratio is not calculable due to negative equity, signaling high risk. Total liabilities exceed assets, indicating solvency issues.

Cash Flow

Cash flows are under pressure, with consistently negative operating and free cash flows. Despite a growth in financing cash flow, the reliance on external financing is unsustainable given the weak free cash flow to net income ratio, which remains negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	471.70M	383.96M	537.40M	472.08M	485.63M	223.01M
Gross Profit	-80.78M	-79.16M	-76.61M	-152.41M	-56.90M	13.08M
EBITDA	-326.79M	-345.62M	-344.16M	-401.86M	-363.86M	-236.72M
Net Income	-378.93M	-308.24M	-297.66M	-489.66M	-271.43M	-309.99M
Balance Sheet
Total Assets	6.62B	6.73B	6.05B	6.00B	6.23B	5.33B
Cash, Cash Equivalents and Short-Term Investments	326.90M	350.85M	58.14M	158.28M	157.39M	334.26M
Total Debt	3.56B	3.93B	3.30B	3.24B	2.73B	2.35B
Total Liabilities	4.70B	5.11B	4.31B	3.99B	3.49B	2.93B
Stockholders Equity	-2.14B	-2.28B	-2.12B	-1.86B	-1.37B	-662.96M
Cash Flow
Free Cash Flow	0.00	-808.58M	-392.17M	-600.47M	-1.12B	-734.47M
Operating Cash Flow	0.00	-397.75M	-276.47M	-216.69M	-359.31M	-229.77M
Investing Cash Flow	0.00	-593.44M	-47.68M	-118.79M	-565.98M	-533.88M
Financing Cash Flow	0.00	1.15B	257.65M	383.09M	642.45M	1.14B

Concord Medical Services Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5.80
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCM, the sentiment is Neutral. The current price of 5.8 is below the 20-day moving average (MA) of 6.13, below the 50-day MA of 6.82, and above the 200-day MA of 5.67, indicating a neutral trend. The MACD of -0.35 indicates Positive momentum. The RSI at 43.08 is Neutral, neither overbought nor oversold. The STOCH value of 52.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CCM.

Concord Medical Services Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMS	64 Neutral	$16.06M	11.31	6.16%	―	35.25%	175.21%
Sector *	52 Neutral	$7.50B	0.31	-61.87%	2.27%	17.10%	1.59%
CCEL	50 Neutral	$40.81M	404.00	93.38%	11.77%	2.33%	―
MODV	49 Neutral	$46.65M	―	-951.52%	―	-0.70%	-2.38%
TOI	47 Neutral	$231.62M	―	-227.77%	―	17.64%	13.86%
PIII	43 Neutral	$45.85M	―	-131.17%	―	9.79%	-47.01%
CCM	39 Underperform	$25.18M	―	14.03%	―	-29.82%	-2.57%